ZIM
ACAD icon

Zacks Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Zacks Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,370
Closed -$945K – 517
2017
Q4 		$945K Buy
31,370
+13,794
+78% +$441K 0.02% 413
2017
Q3 		$662K Buy
+17,576
New +$572K 0.02% 436

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Zacks Investment Management's ACAD Position: Q1 2018 in Review

Zacks Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2018, closing a stake of 31,370 shares — an estimated $945K sold.

Zacks Investment Management first reported a position in ACAD in Q3 2017 and held it in 2 quarters. The position peaked at $945K in Q4 2017. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

  • Zacks Investment Management reported no remaining Acadia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Zacks Investment Management sold 31,370 Acadia Pharmaceuticals shares in Q1 2018, an estimated $945K.
  • Zacks Investment Management first reported a position in Acadia Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Zacks Investment Management's Acadia Pharmaceuticals position peaked at $945K in Q4 2017.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on Zacks Investment Management's 13F filing for Q1 2018, filed 14 May 2018.